Certara Introduces Integral, its Next-generation Data Repository
It is a multi-functional, cloud-based, 21 CFR Part 11 compliant platform for clinical pharmacology, pharmacometrics and clinical operations professionals.
Explore Our Scientific Resource Library
Certara Appoints Dr. William F. Feehery as Chief Executive Officer
Certara® the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, announced today that it has appointed Dr. William F. Feehery as its new Chief Executive Officer (CEO) and a member of the Certara Board of Directors, effective June 3, 2019.
Certara Adds 4 Global Leaders to its Simcyp PBPK, QSP and QSTS M&S Division
New executives’ scientific, operational and consulting expertise will support Simcyp’s footprint in drug development and regulatory decision-making.
Solution:
PBPK Modeling & Simulation, Systems Pharmacology
Global Regulatory Agencies Increase Adoption of Phoenix PK/PD M&S Software for Drug Reviews
PRINCETON, NJ – Apr. 4, 2019- ANVISA, MHRA and PMDA join EMA, FDA, NMPA and TGA in expanding their Phoenix software licenses to evaluate drug regulatory submissions
Solution:
PBPK Modeling & Simulation
Certara Scientists Advance ASCPT Agenda: From Molecule to Patient
PRINCETON, NJ – Mar. 13, 2019 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that its pharmacokinetic/pharmacodynamic (PK/PD), quantitative systems pharmacology (QSP) and physiologically-based pharmacokinetic (PBPK) modeling experts will participate in 21 sessions at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2019 […]
Certara Showcases Multi-faceted Approach to Improving Drug Safety Assessments at the Society of Toxicology Annual Meeting
PRINCETON, NJ – Mar. 8, 2019 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that it will be showcasing its multi-faceted – technology, service and regulatory science – approach to improving new drug safety assessments at the Society of Toxicology (SOT) Annual Meeting and […]
Centers for Disease Control and Prevention (CDC) Selects Certara to Develop Technology Platform to Strengthen the Agency’s Death Investigation and Surveillance Systems
PRINCETON, NJ – March 5, 2019 – Certara will partner with CDC to create OpenMDI (Open Medicolegal Death Investigation), a national system that will collect and share mortality data efficiently, allowing CDC to respond rapidly to critical public health priorities, such as tracking and understanding the toxicology behind drug overdoses from opioids.
.
Certara Launches Version 19.1 of its D360 Scientific Informatics Platform
PRINCETON, NJ – February 21, 2019 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced the launch of version 19.1 of its flagship scientific informatics platform D360.
Solution:
Scientific Informatics
Certara Advances Global Initiative to Take Model-Informed Precision Dosing (MIPD) Into the Clinic
PRINCETON, NJ – February 7, 2019 – Certara has recently published four peer-reviewed MIPD papers; its progress is generating strong interest from industry, health care professionals and regulators.
Solution:
Model-informed Drug Development
Certara Appoints Justin Edge as President of its Synchrogenix Division
PRINCETON, NJ – February 4, 2019 – Certara today announced that Justin Edge has joined Certara as President of Synchrogenix, the company’s regulatory science division.
Solution:
Regulatory & Medical Writing